The German drugmaker will pay the NIH $791.5 million, while the University of Pennsylvania will get up to $467 million ...
Acasunlimab is under clinical development by BioNTech and currently in Phase III for Non-Small Cell Lung Cancer.
BNT-325 is under clinical development by BioNTech and currently in Phase II for Non-Small Cell Lung Cancer. According to GlobalData, Phase II drugs for Non-Small Cell Lung Cancer have a 38% phase ...
The BioNTech SE ADR BNTX inched 0.42% higher to $115.79 Friday, on what proved to be an all-around great trading session for ...
Penn has reached an agreement to resolve a dispute over Covid-19 royalties the Philadelphia university alleged it was owed.
BioNTech has entered into two separate settlement agreements with the U.S. National Institutes of Health and the University ...
The new $467 million includes $400 million in royalties for the Pfizer-BioNTech vaccine from 2020 through 2023.
Seeking Alpha on MSN9d
BioNTech inks $1B settlements with NIH and Penn to resolve COVID vaccine royalty claimsBioNTech (BNTX) stock slipped after signing $1B deals with NIH and the University of Pennsylvania to resolve COVID vaccine ...
German pharmaceutical company BioNTech has agreed to pay a combined sum of more than $1.2 billion to resolve separate ...
DPA International on MSN9d
BioNTech and Pfizer to pay Covid-19 vaccine settlements in USThe German pharmaceutical company BioNTech announced on Friday that it has reached settlements in the US to resolve a ...
Big moves are shaking up BioNTech (NASDAQ:BNTX) this week, and investors are taking notice. The German biotech heavyweight ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback